Aug 23, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Jul 25, 2019
Robust Use of Janssen's Tremfya and Positive Early Launch Metrics for AbbVie's Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights
Jun 06, 2019
Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology
Jun 05, 2019
Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology
May 14, 2019
Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting
Mar 11, 2019
New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis
Mar 01, 2019
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Feb 04, 2019
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Jan 14, 2019
Janssen's Stelara and Pfizer's Xeljanz Battle Takeda's Entyvio to Claim the Preferred Alternate Mechanism of Action Position in Inflammatory Bowel Disease Patients Who Are Being Switched from Their Current Treatment
Jan 04, 2019
Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF Alpha Antibody Fragment
Dec 13, 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Nov 12, 2018
NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira(R) (adalimumab)
Oct 25, 2018
Global TNF Inhibitors Market 2019-2023 with AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer & UCB Dominating
Oct 24, 2018
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Oct 23, 2018
New Phase 2 Data Show Stelara® (Ustekinumab) Sustained Improvement In Disease Activity In Adults With Systemic Lupus Erythematosus Through One Year
Oct 22, 2018
Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally
Oct 21, 2018
ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
Oct 19, 2018
InDex Pharmaceuticals Publishes Post-hoc Analysis of the COLLECT Study
Oct 15, 2018
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
Oct 09, 2018
New Phase 3 Data Show Single Dose Of STELARA® (ustekinumab) Induces Clinical Remission And Response In Adults With Moderate To Severe Ulcerative Colitis